20:49 , Oct 13, 2017 |  BioCentury  |  Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma Mouse studies suggest combining Mekinist trametinib with MAPK and CRAF inhibitors could help treat BRAF-dependent lung cancer and melanoma. In six PDX mouse models of BRAF-dependent lung cancer and five of BRAF-dependent...